Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02716272
Recruitment Status : Completed
First Posted : March 23, 2016
Last Update Posted : February 10, 2021
Sponsor:
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique